And then there were two. On January 1, Abbott Laboratories
(NYSE:ABT) split into two companies with two different stocks.
(NYSE:ABBV) is the drug company that owns Humira, a big selling injectable rheumatoid arthritis drug that produced $7.93 billion in sales in 2011. Abbott Laboratories is the medical device, diagnostics, and nutritionals company.
Do you want to hold both or sell one or the other?
In the near term -- say, the next two years -- AbbVie has all the risk and Abbott Laboratories has all the growth. In Jubak's Picks
, I'm going to sell my shares of AbbVie and use the proceeds to buy more shares of Abbott Laboratories to restore the pre-split position size in Abbott.
AbbVie CFO William Chase laid out the case for AbbVie in an interview with Bloomberg today. It's not an especially attractive story over the next two years.
Over those two years, Chase said, the company will be in what is basically a holding pattern, as AbbVie nets out increased revenue from Humira and Androgel with losses of about $2.5 billion in sales as drug patents expire.
The company's hope is that new products now in the pipeline will start to kick in around 2015 and put the company back on a growth track. Those products include the company's hepatitis C drug (which does not require interferon), a gel for Parkinson's, a multiple sclerosis drug, and a drug for endometriosis. The four, Chase projected, would produce $4 billion to $6 billion per year in peak sales.
And why would investors be willing to hang onto AbbVie shares until the pipeline produces? The company's shares now pay $1.60 in dividends, and the company intends to grow that dividend.
Contrast that high-risk growth strategy with the very clear growth trend in most of the four units -- diagnostics, medical devices, generic drugs, and nutritionals -- at the core of the post-split Abbott Laboratories.
Of these, the star is the nutrition business, which is projected to grow by a compounded annual 35% per year powered by the company's growth in China, India, and other developing economies. (The post-split Abbott Laboratories gets about 40% of its revenue from developing economies.) Rising income levels are driving sales of infant and adult nutritionals in emerging markets, and Abbott has been increasing its penetration, especially in China, Southeast Asia, and Latin America through moves like the 2009 acquisition of the nutritional business of India's Wickhardt. Margins in this business are likely to increase as the company is able to spread the costs of growth over an increasing sales base.
Abbott's generic drug business is another unit taking advantage of faster growth in developing than developed economies. In 2010, Abbott acquired Solvay Pharmaceuticals, which brought the company a portfolio of branded generic drugs and expanded Abbott's presence in Eastern Europe, Russia, India, and Brazil.
This isn't to say that the post-split Abbott Laboratories doesn't have problems-especially in its medical device business. For example, Abbott's drug-eluting stents are a market leader, but sales have been under pressure and prices have been falling.
I think the problems in the division are certainly fixable through an acquisition or two, but the challenge will be buying the right technologies at the right price in a market where customers are under pressure to cut costs.
I still think that adding up the pluses and minuses comes out very strongly in favor of the post-split Abbott Laboratories, and I'll be adding to that position by selling my shares of AbbVie today.
Editor's Note: This article was written by Jim Jubak of MoneyShow.
Below, find some more great investing and trading content from MoneyShow:
A Commodity ETF Growing Like a Weed
A Partnership That Has No Limits
The Week Ahead: What Do Sectors Say About the Economy?
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.